Drugs / verbrinacogene setparvovec
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05164471 | Dec 2021 → May 2023 | hemophilia B | Spur Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03641703 | Jul 2018 → May 2023 | hemophilia B | Spur Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03369444 | Dec 2017 → Oct 2020 | hemophilia B | University College, London | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | verbrinacogene setparvovec | “BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to...” PMID 35857660 ↗ Jul 2022 |
| Known as | FLT180a | “FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B” NCT05164471 ↗ |
| Action | Restore | “FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize...” PMID 35857660 ↗ Jul 2022 |
| Modality | Gene therapy (AAV / viral vector) | “FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy” PMID 35857660 ↗ Jul 2022 |
| Route | Intravenous | “FLT180a was administered as a single dose, slow intravenous (IV) infusion into a peripheral vein.” NCT03369444 ↗ |